Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Traumatic Brain Injury Treated By Alzheimer's Disease Drug
The destructive cellular pathways activated in Alzheimer"s disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center (GUMC). They say this finding suggests that novel therapy might successfully target both conditions.

Yaupon Therapeutics Completes Patient Enrollment For Pivotal Phase 2 Study Of Clearazide For Treatment Of Cutaneous T-cell Lymphoma
Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being conducted under a Special Protocol Assessment (SPA) with the FDA, has enrolled 260 patients in 13 of the top cancer centers in the US. Yaupon expects the last patient to complete treatment in the study by June of 2010 and, assuming positive results, will file its NDA shortly thereafter.
News of the day
New Training And Education Programme Introduced For The Scientific Workforce In Genetics, UK
A new education programme has been developed to provide enhanced training in genetic technologies and clinical applications for healthcare scientists working in laboratory genetics, Health Minister Ann Keen announced.
Diagnostics

Which Country Ranks Highest In Biotech Innovation

In a first of its kind study, Scientific American cut through the marketing messages to take a hard look at what countries across the globe are doing to bolster biotech programs within their borders. Many rankings compare Europe, Asia, and the US -- the Scientific American Worldview: A Global Biotechnology Perspective digs deeper, examining all the elements that impact overall biotech innovation. You might be surprised by some of the results. Although it"s probably no surprise that overall, the US had the highest final score, it did not come out on top for all five benchmarks: intellectual property, enterprise support, the intensity of a country"s biotech activities, education/workforce, and infrastructure. - Finland, Israel, Singapore, and Sweden came out on top in terms of the infrastructure available for biotechs. - Singapore and Switzerland scored better than the US when it came to education/workforce. - Iceland ranked highest on the "intensity" score, which measured the intensity -- public companies per capita, portion of overall R&D spending used for biotech, etc. -- of a country"s biotech activities. - Although the US came out on top in intellectual property protections, Belgium, Canada, Denmark, France, Ireland, Italy, Japan, the Netherlands, and the UK weren"t too far behind. The small country of Denmark, however, leads the world in the number of biotech patents per member of the population. To view a complete copy of the report, please visit http://www.saworldview.com. Scientific American


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009